DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

Search

Exponent Inc

Uždarymo kaina

SektoriusPramonės sektorius

69.41 -1.17

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

69.13

Max

70.24

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.5M

28M

Pardavimai

5.2M

147M

P/E

Sektoriaus vid.

35.084

40.202

Dividendų pajamingumas

1.65

Pelno marža

19.062

Darbuotojai

976

EBITDA

6.8M

41M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+21.67% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.65%

2.12%

Kitas dividendų mokėjimo data

2026-03-20

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

174M

3.6B

Ankstesnė atidarymo kaina

70.58

Ankstesnė uždarymo kaina

69.41

Naujienos nuotaikos

By Acuity

61%

39%

378 / 454 reitingas Industrials

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Exponent Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-31 22:20; UTC

Pagrindinės rinkos jėgos

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025-12-31 17:31; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025-12-31 16:30; UTC

Pagrindinės rinkos jėgos

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025-12-31 15:19; UTC

Pagrindinės rinkos jėgos

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025-12-31 15:17; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025-12-31 14:37; UTC

Pagrindinės rinkos jėgos

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025-12-31 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-31 21:13; UTC

Įsigijimai, susijungimai, perėmimai

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025-12-31 20:40; UTC

Rinkos pokalbiai

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025-12-31 20:22; UTC

Rinkos pokalbiai

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025-12-31 19:50; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025-12-31 19:31; UTC

Rinkos pokalbiai

Precious Metals Cap Off Record Runs -- Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025-12-31 17:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025-12-31 17:16; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025-12-31 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-31 17:00; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025-12-31 15:57; UTC

Įsigijimai, susijungimai, perėmimai

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025-12-31 15:54; UTC

Rinkos pokalbiai

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025-12-31 15:02; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025-12-31 14:40; UTC

Įsigijimai, susijungimai, perėmimai

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025-12-31 14:20; UTC

Rinkos pokalbiai

Crude Futures On Track to End the Year With Losses -- Market Talk

2025-12-31 13:46; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025-12-31 13:01; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025-12-31 11:10; UTC

Rinkos pokalbiai

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025-12-31 10:46; UTC

Rinkos pokalbiai

Euro on Track For Strong Annual Performance -- Market Talk

2025-12-31 10:25; UTC

Rinkos pokalbiai

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025-12-31 10:23; UTC

Rinkos pokalbiai

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025-12-31 09:33; UTC

Rinkos pokalbiai

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Akcijų palyginimas

Kainos pokytis

Exponent Inc Prognozė

Kainos tikslas

By TipRanks

21.67% į viršų

12 mėnesių prognozė

Vidutinis 85.5 USD  21.67%

Aukščiausias 90 USD

Žemiausias 81 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Exponent Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

75.29 / 78.99Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

378 / 454 reitingas Pramonės sektorius

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Exponent Inc

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering and sciences, buildings and structures, civil engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, thermal sciences, and vehicle engineering. The Environmental and Health segment offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. The company offers approximately 90 technical disciplines to solve pressing and complicated challenges facing stakeholders. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors of the economy. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.
help-icon Live chat